Barbara Galaini Net Worth

The estimated Net Worth of Barbara Galaini is at least $6.2 Thousand dollars as of 12 November 2021. Ms. Galaini owns over 10,000 units of Tyme Technologies Inc stock worth over $6,200 and over the last 6 years she sold TYME stock worth over $0. In addition, she makes $0 as Principal Financial Officer, Principal Accounting Officer, and Corporate Controller at Tyme Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Galaini TYME stock SEC Form 4 insiders trading

Barbara has made over 2 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of TYME stock worth $9,500 on 12 November 2021.

The largest trade she's ever made was buying 10,000 units of Tyme Technologies Inc stock on 12 November 2021 worth over $9,500. On average, Barbara trades about 2,500 units every 110 days since 2018. As of 12 November 2021 she still owns at least 20,000 units of Tyme Technologies Inc stock.

You can see the complete history of Ms. Galaini stock trades at the bottom of the page.

Barbara Galaini biography

Barbara Galaini has been appointed as Principal Financial Officer, Principal Accounting Officer, Corporate Controller of the Company effective 9/30/2020. She has served as the Principal Accounting Officer of Tyme since August 2018 and the Company’s Corporate Controller since April 2018. Before joining the Company, Ms. Galaini was the Chief Accounting Officer of the Americas for Avolon Holdings, a global aircraft leasing company from April 4, 2017 to April 4, 2018. Prior to that she was employed at CIT Bank for more than 25 years in various financial roles, including segment Chief Financial Officer and most recently as Senior Vice President and Controller of the Transportation Finance unit since 2009. Ms. Galaini has extensive experience in structured finance and leasing transactions, acquisition and divestitures and finance integration.

How old is Barbara Galaini?

Barbara Galaini is 62, she's been the Principal Financial Officer, Principal Accounting Officer, and Corporate Controller of Tyme Technologies Inc since 2020. There are 6 older and 12 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.

What's Barbara Galaini's mailing address?

Barbara's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.

Insiders trading at Tyme Technologies Inc

Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, and Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.

What does Tyme Technologies Inc do?

Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.

With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.

Complete history of Ms. Galaini stock trades at Tyme Technologies Inc

Tyme Technologies Inc executives and stock owners

Tyme Technologies Inc executives and other stock owners filed with the SEC include:

• James Biehl,
  Chief Legal Officer and Corporate Secretary
• Michele Korfin,
  Chief Operating Officer
• Steve Hoffman,
  Chairman of the Board, Chief Executive Officer, Chief Science Officer
• Steven E. Hoffman,
  Co-Founder, Chairman & Chief Science Officer
• James Biehl J.D.,
  Chief Legal Officer & Sec.
• Dr. Jonathan M. Eckard,
  Chief Bus. Officer
• Richard Cunningham,
  CEO & Director
• David Carberry,
  Independent Director
• Donald Degolyer,
  Independent Director
• Gerald Sokol,
  Independent Director
• Timothy Tyson,
  Independent Director
• Douglas Michels,
  Independent Director
• Paul Sturman,
  Independent Director
• Jonathan Eckard,
  Chief Business Officer
• Giuseppe Del Priore,
  Chief Medical Officer
• Barbara Galaini,
  Principal Financial Officer, Principal Accounting Officer, Corporate Controller
• Frank L. Porfido,
  Chief Financial Officer
• Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
  Acting Chief Medical Officer
• Dr. John M. Rothman,
  Exec. VP of Product Devel.
• John Zucaro P.E.,
  Sr. VP of CMC
• Tommy G Thompson,
  Director
• Christine D. Baker,
  Director
• John M. Rothman,
  EVP, Product Development
• Michael Demurjian,
  10% owner
• Ben R Taylor,
  President, CFO
• Tornout Jan M Van,
  Acting Chief Medical Officer
• Christopher F Brown,
  10% owner
• Frank L. Porfido,
  Chief Financial Officer
• Richard Anthony Cunningham,,
  Chief Executive Officer